US equities |
SPCX $174.30 ▲+1.88% NVDA $241.44 ▲+1.06% MU $1,062.98 ▼-0.09% AMD $655.78 ▲+3.80% MRVL $294.38 ▲+8.53% SNDK $1,669.04 ▼-2.06% AVGO $377.73 ▲+4.20% TSLA $380.83 ▲+0.55%
FinancialContent

Sanofi - American Depositary Shares (NQ:SNY)

39.78 +0.27 (+0.68%)
Delayed Quote Updated: 11:42 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
News headline image
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion ↗
Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the... 
Via MarketBeat
News headline image
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is Regeneron Stock a Bargain Below $800? ↗
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine ↗
Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global... 
Via MarketBeat
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability ↗
Via Chartmill
Sanofi (NASDAQ:SNY) Screens as Undervalued Value Stock with Solid Profitability ↗
Via Chartmill
Sanofi-ADR (NASDAQ:SNY) Offers a High Dividend Yield With Strong Underlying Quality ↗
Via Chartmill
News headline image
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss ↗
Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the... 
Via MarketBeat
Topics Intellectual Property
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile ↗
Via Chartmill
Sanofi-ADR (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals ↗
Via Chartmill
SANOFI-ADR (NASDAQ:SNY): A Quality Dividend Stock with a 5.31% Yield and Strong Fundamentals ↗
Via Chartmill
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
From BioMedWire
Via GlobeNewswire
News headline image
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗
They could both outperform the market over the medium term, but one appears to have a clear edge. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity? ↗
The company has increased its dividend for 30 consecutive years. 
Via The Motley Fool
News headline image
Sanofi Q2 Earnings Call Highlights ↗
Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also... 
Via MarketBeat
Topics Earnings
News headline image
The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.) ↗
Add the effect of stock buybacks to the dividend, and you're looking at a total yield approaching 11%. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
3 High-Yield Dividend Stocks to Buy and Hold ↗
All three can be bought on the dip. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. 
Via The Motley Fool
News headline image
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows ↗
These stocks pay between 5.3% and 6.7% in dividends. 
Via The Motley Fool
Topics Intellectual Property
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Via Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Via Investor Brand Network
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
From BioMedWire
Via GlobeNewswire
News headline image
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗
The stock looks cheap, but appearances can be deceiving. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
1 Dirt Cheap Growth Stock to Buy Right Now ↗
Sanofi is generating some solid growth and it trades at an incredibly low valuation. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Investors can find much better opportunities. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >